Clinical Trial Update: Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

This is a completed Phase 2 study evaluating the safety, tolerability and efficacy of the monoclonal antibody CT-011 in patients with metastatic melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CT-011

Snippet

Sponsor: Medivation, Inc. | Conditions: Melanoma, Malignant Melanoma | Phase 2 | Status: COMPLETED